Tag: evinacumab

1. After 16 weeks of treatment, patients who received evinacumab had decreases in low density lipoprotein (LDL) of up to 50% depending on dose, while those who received placebo experienced virtually no change. 2. The method of administration, subcutaneous vs. intravenous, did not appear to impact the agent’s efficacy or...
1. Evinacumab significantly lowered low-density lipoprotein (LDL) cholesterol levels in patients with homozygous familial hypercholesterolemia. 2. Patients receiving evinacumab did not demonstrate additional serious adverse events compared to the control group. Evidence Rating Level: 1 (Excellent) Study Rundown: Homozygous familial hypercholesterolemia occurs due to a loss-of-function variant in the low-density lipoprotein (LDL)...
1. Evinacumab significantly lowered low-density lipoprotein (LDL) cholesterol levels in patients with homozygous familial hypercholesterolemia. 2. Patients receiving evinacumab did not demonstrate additional serious adverse events compared to the control group. Evidence Rating Level: 1 (Excellent) Study Rundown: Homozygous familial hypercholesterolemia occurs due to a loss-of-function variant in the low-density lipoprotein (LDL)...